Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00156013 · ClinicalTrials.gov registry record · Phase 1
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
A Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell, sponsored by Oncology Specialists, S.C..
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00156013: Completed Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell, sponsored by Oncology Specialists, S.C..
NCT00156013 is a Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell that has completed, run by Oncology Specialists, S.C.. The registered enrollment target is 33 participants, below the 389-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00156013, a Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell, has completed, sponsored by Oncology Specialists, S.C..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to develop new treatment for non-hodgkin's lymphoma in subjects whose cancer has returned or resisted treatment with chemotherapy. The investigational drug clofarabine is being used in this study. An investigational drug is one that has not been approved by the United States Food and Drug Administration (FDA).
Primary Outcome
Maximum Tolerated Dose for Clofarabine. Cohorts of 3 patients each will receive doses of clofarabine increased in increments as follows: 4, 6, 8, 10, 12,…etc mg/m2/day for 5 days. The dose level immediately below the MTD will be used to treat patients in the Phase II part of the study. Starting dose of 4 mg/m2.
Conditions Studied
Interventions
- DRUG CLOFARABINE
Study Locations (1)
Illinois
- Oncology Specialists, SC - Park Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
What the finished NCT00156013 record still lists
NCT00156013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 389-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which CLOFARABINE is the first listed.
NCT00156013 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00156013 about?
NCT00156013 is a clinical study titled "Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)". This research is being done to develop new treatment for non-hodgkin's lymphoma in subjects whose cancer has returned or resisted treatment with chemotherapy. The investigational drug clofarabine is being used in this study. An investigational drug is one that has not been approved by the United Sta...
What is the current status of trial NCT00156013?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2005-09. Estimated completion is 2010-04.
What conditions does trial NCT00156013 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell.
What interventions are being tested in trial NCT00156013?
The interventions under investigation include: CLOFARABINE (DRUG).
Who is sponsoring clinical trial NCT00156013?
This trial is sponsored by Oncology Specialists, S.C., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00156013 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00156013's enrollment target sits among peer trials
33 42nd of 58 higher than 15 of 58 other Lymphoma, Non-Hodgkin trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia